• Canbridge annual report for year ended Dec. 31, 2025 highlighted shift toward rare-disease focus, supported by strategic partnership with Baheal Medical signed in August 2025.
• Collaboration named Baheal subsidiaries as exclusive CSO for Hunterase, Livmarli, Gaurunning across mainland China, Hong Kong, Macau; Canbridge received RMB 50 million engagement fee.
• Baheal unit also subscribed 74,971,468 shares for about HK$ 100 million, strengthening liquidity for commercialization execution.
• Gaurunning won NMPA marketing clearance in May 2025, then entered China first commercial health insurance innovative drug list in December 2025.
• Cost base fell across R&D, selling, administrative lines as Canbridge streamlined operations to 41 employees, while management flagged non-recurring gains as key driver of IFRS profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260429-12136721), on April 29, 2026, and is solely responsible for the information contained therein.